Costa Rica
Tuberculosis profile
Population  2012 4.8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.038 (0.034–0.043) 0.8 (0.7–0.89)
Mortality (HIV+TB only) <0.01 (<0.01–0.012) 0.21 (0.17–0.25)
Prevalence  (includes HIV+TB) 0.6 (0.22–1.2) 12 (4.7–24)
Incidence  (includes HIV+TB) 0.51 (0.44–0.58) 11 (9.3–12)
Incidence (HIV+TB only) 0.064 (0.056–0.072) 1.3 (1.2–1.5)
Case detection, all forms (%) 93 (82–110)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 257 (56) Relapse 17 (77)
Smear-negative 29 (6) Treatment after failure 2 (9)
Smear-unknown / not done 70 (15) Treatment after default 3 (14)
Extrapulmonary 102 (22) Other 0 (0)
Other 0 (0)      
Total new 458   Total retreatment 22  
           
Other (history unknown) 0        
Total new and relapse 475   Total cases notified 480  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.4 1.3 2.8
Age < 15 4 22 7
Laboratories 2012
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 14.6
Drug susceptibility testing (per 5 million population) 1.0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 87  
Retreatment 81  
TB/HIV 2012 Number (%)
TB patients with known HIV status 453 (94)
HIV-positive TB patients 49 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.5 (0.42–3.9) 4.5 (0.12–23)
MDR-TB cases among notified pulmonary
TB cases
5 (2–14) 1 (0–5)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 273 (95%) 22 (100%) 295
Laboratory-confirmed MDR-TB cases 0 1 1
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data